카바 관련 과각성 및 인지적 불면증

카바의 GABA성 및 도파민성 활성은 이 불면증 아형을 특징짓는 인지적 및 생리적 과각성을 줄이는 데 도움이 될 수 있습니다. 과각성 관련 결과에 대한 직접적 근거는 제한적이지만, 항불안 데이터는 이를 뒷받침합니다. 간독성 위험으로 신중한 의료 감독이 필요합니다.

𝕏 LinkedIn

<\/script>\n

`; }, get iframeSnippet() { const domain = 'sleepcited.com'; const params = 'ingredient\u003Dkava\u0026condition\u003Dhyperarousal\u002Dinsomnia'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style

Widget powered by . Free, no account required.

결론

Key Study Findings

Case Reports n=1 6 weeks

Diagnosing Acute Kava Dermopathy: A Case Report of a Characteristic Cutaneous Eruption.

Dose: None vs: None Outcome: acute kava dermopathy with sebaceous gland necrosis 효과: None None

대상 집단: 41-year-old Australian woman consuming kava for anxiety and insomnia

Case Reports n=1 Open-label

Severe kava withdrawal managed with phenobarbital.

Dose: None vs: None Outcome: Resolution of kava withdrawal symptoms 효과: None None

대상 집단: 45-year-old man with kava and kratom withdrawal

Other Double-blind

The potential of AB-free kava in enabling tobacco cessation via management of abstinence-related stress and …

Dose: AB-free kava extract vs: Placebo Outcome: Tobacco cessation via stress/insomnia management 효과: None None

대상 집단: Adult smokers (trial protocol)

Controlled Clinical Trial

Acute oral toxicity, antinociceptive and antimicrobial activities of kava dried extracts and synthetic kavain.

Dose: None vs: Vehicle control Outcome: Acute oral toxicity, antinociceptive activity 효과: None None

대상 집단: Animal model

Systematic Review

The Impact of Complementary and Alternative Medicine on Insomnia: A Systematic Review.

Dose: None vs: None Outcome: Sleep quality improvement 효과: None None

대상 집단: Insomnia patients

Review

Calm Down With Kava: What Clinicians Need to Know.

Dose: None vs: None Outcome: None 효과: None None

대상 집단: Kava users

Key Statistics

연구

2043

참여자

↔

Mixed

등급

Referenced Papers

Diagnosing Acute Kava Dermopathy: A Case Report of a Characteristic Cutaneous Eruption. Case Report

The Medical journal … 2026

Severe kava withdrawal managed with phenobarbital. Case Report

The American journal … 2025 1 인용

The potential of AB-free kava in enabling tobacco cessation via management of abstinence-related stress and insomnia: study protocol for a … Other

BMC complementary medicine … 2024 1 인용

An Updated Review on the Psychoactive, Toxic and Anticancer Properties of Kava. Review

Journal of clinical … 2022 27 인용

The Impact of Complementary and Alternative Medicine on Insomnia: A Systematic Review. Review

Cureus 2022 17 인용

Acute oral toxicity, antinociceptive and antimicrobial activities of kava dried extracts and synthetic kavain. Other

Natural product research 2022 3 인용

Calm Down With Kava: What Clinicians Need to Know. Other

Journal of psychosocial … 2022 2 인용

Nutraceuticals for Sleep Disorders. Review

Combinatorial chemistry & … 2021 16 인용

The Veterans Administration and Department of Defense clinical practice guidelines for the diagnosis and management of sleep disorders: what does … Other

Journal of clinical … 2020 17 인용

Enzymes and Pathways of Kavain Bioactivation and Biotransformation. Other

Chemical research in … 2019 6 인용

Natural Products from Single Plants as Sleep Aids: A Systematic Review. Systematic Review

Journal of medicinal … 2018 19 인용

Herbal medicine for insomnia: A systematic review and meta-analysis. Meta-Analysis

Sleep medicine reviews 2015 152 인용

Psychophytomedicine: an overview of clinical efficacy and phytopharmacology for treatment of depression, anxiety and insomnia. Review

Holistic nursing practice 2014 10 인용

Toxicokinetics of kava. Other

Advances in pharmacological … 2011 79 인용

Flavokawain B, the hepatotoxic constituent from kava root, induces GSH-sensitive oxidative stress through modulation of IKK/NF-kappaB and MAPK signaling pathways. Other

FASEB journal : … 2010 110 인용

Medicinal plants for insomnia: a review of their pharmacology, efficacy and tolerability. Review

Journal of psychopharmacology … 2005 176 인용

An internet-based randomized, placebo-controlled trial of kava and valerian for anxiety and insomnia. RCT

Medicine 2005 128 인용

Effects of kava-kava extract on the sleep-wake cycle in sleep-disturbed rats. Other

Psychopharmacology 2005 36 인용

Safety and efficacy of herbal sedatives in cancer care. Review

Integrative cancer therapies 2004 59 인용

Saccade and cognitive impairment associated with kava intoxication. Other

Human psychopharmacology 2003 45 인용

Over-the-counter sleeping pills: a survey of use in Hong Kong and a review of their constituents. Review

General hospital psychiatry 2002 38 인용

Kava and valerian in the treatment of stress-induced insomnia. Other

Phytotherapy research : … 2001 74 인용

Stress-induced insomnia treated with kava and valerian: singly and in combination. Other

Human psychopharmacology 2001 52 인용

[Hematogenous contact eczema cause by phytogenic drugs exemplified by kava root extract]. Case Report

Der Hautarzt; Zeitschrift … 1996 22 인용

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

일반적으로 사용되는 용량

sleep:: 120-250 mg kavalactones/day, 1-2 hrs before bed

상한량: 250 mg kavalactones/day (European guidelines); limited to 3 months continuous use

연구에서 사용된 용량

용량	기간	효과	N
None	6 weeks	Negative	1
None	--	Positive	1
AB-free kava extract	--	Mixed	--
None	--	Positive	--
None	--	Mixed	--
None	--	Mixed	--
None	--	Mixed	--
not specified	--	Positive	--

권장 복용 시간: 1-2 hours before bed; avoid daily use beyond 3 months without medical supervision

Safety & Side Effects

보고된 부작용

⚠ Drowsiness and reduced coordination
⚠ Hepatotoxicity (rare but serious — consult healthcare provider)
⚠ Skin rash (kava dermopathy) with chronic high-dose use
⚠ GI discomfort

알려진 상호작용

● Alcohol — increased hepatotoxicity risk and CNS depression
● Hepatotoxic medications (acetaminophen, statins) — additive liver stress
● Benzodiazepines and sedatives — additive CNS depression
● CYP450 substrates (2E1, 1A2, 2D6) — kavalactones may inhibit metabolism
● Levodopa and dopaminergic drugs — kava may reduce efficacy

일일 최대 섭취 허용량: 250 mg kavalactones/day (European guidelines); limited to 3 months continuous use

건강기능식품을 복용하기 전에 반드시 의료 전문가와 상담하십시오.

Frequently Asked Questions

Does 카바 help with 과각성 및 인지적 불면증?

Based on 23 studies with 2,043 participants, there is strong evidence from multiple clinical trials that 카바 may support 과각성 및 인지적 불면증 management. Our evidence grade is A (Strong Evidence).

How much 카바 should I take for 과각성 및 인지적 불면증?

Studies have used various dosages. A commonly studied range is 120-250 mg kavalactones/day, 1-2 hrs before bed. Always consult your healthcare provider before starting any supplement regimen.

Are there side effects of 카바?

Reported side effects may include Drowsiness and reduced coordination, Hepatotoxicity (rare but serious — consult healthcare provider), Skin rash (kava dermopathy) with chronic high-dose use, GI discomfort. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.

How strong is the evidence for 카바 and 과각성 및 인지적 불면증?

We rate the evidence as Grade A (Strong Evidence). This rating is based on 23 peer-reviewed studies with 2,043 total participants. The overall direction of effect is mixed.

Related Evidence

카바 다른 건강 상태에 대한 근거

불면증 A 불안 관련 수면 문제 A

한눈에 보기

카바의 GABA성 및 도파민성 활성은 이 불면증 아형을 특징짓는 인지적 및 생리적 과각성을 줄이는 데 도움이 될 수 있습니다. 과각성 관련 결과에 대한 직접적 근거는 제한적이지만, 항불안 데이터는 이를 뒷받침합니다. …

Evidence Strength92%

High confidence

연구 분석

RCT (1)Meta (1)Other (21)

대안 비교

이 건강 상태에 대한 다른 성분의 비교 결과를 확인하세요.

모든 성분 보기: 과각성 및 인지적 불면증

자세히 알아보기

FDA 면책 조항: 이 내용은 미국 식품의약국(FDA)의 평가를 받지 않았습니다. 이 웹사이트의 제품 및 정보는 질병의 진단, 치료, 완치 또는 예방을 목적으로 하지 않습니다. 제시된 근거 등급은 발표된 동료 심사 연구에 대한 우리의 분석에 기반하며, 의학적 조언을 구성하지 않습니다. 건강기능식품 복용을 시작하기 전에 반드시 의료 전문가와 상담하십시오.